使用18F-氟米索硝唑PET/MR成像评估贝伐单抗对复发性间变性星形细胞瘤患者的生物学反应。
Assessing Biological Response to Bevacizumab Using 18F-Fluoromisonidazole PET/MR Imaging in a Patient with Recurrent Anaplastic Astrocytoma.
作者信息
Barajas Ramon F, Pampaloni Miguel H, Clarke Jennifer L, Seo Youngho, Savic Dragana, Hawkins Randall A, Behr Spencer C, Chang Susan M, Berger Mitchel, Dillon William P, Cha Soonmee
机构信息
Department of Radiology and Biomedical Imaging, University of California, San Francisco, 505 Parnassus Avenue, M-391, San Francisco, CA 94143-0628, USA.
Department of Neurological Surgery, University of California, San Francisco, 505 Parnassus Avenue, Room 779 M, San Francisco, CA 94143-0112, USA.
出版信息
Case Rep Radiol. 2015;2015:731361. doi: 10.1155/2015/731361. Epub 2015 Feb 22.
We present our initial experience in using single modality fluoromisonidazole (FMISO) PET/MR imaging to noninvasively evaluate the biological effects induced by bevacizumab therapy in a patient treated for recurrent high grade glioma. In this index patient, bevacizumab therapy resulted in the development of nonenhancing tumor characterized by reduced diffusion and markedly decreased FMISO uptake in the setting of maintained CBF and CBV. These observations suggest that the dynamic biological interplay between tissue hypoxia and vascular normalization occurring within treated recurrent high grade glioma can be captured utilizing FMISO PET/MR imaging.
我们展示了使用单模态氟米索硝唑（FMISO）PET/MR成像对一名复发性高级别胶质瘤患者进行贝伐单抗治疗诱导的生物学效应进行无创评估的初步经验。在这名索引患者中，贝伐单抗治疗导致出现了无强化肿瘤，其特征为扩散降低且在脑血流量（CBF）和脑血容量（CBV）保持不变的情况下FMISO摄取显著减少。这些观察结果表明，利用FMISO PET/MR成像可以捕捉到复发性高级别胶质瘤治疗过程中组织缺氧与血管正常化之间动态的生物学相互作用。
Zotero 插件